OBJECTIVE: Associations between 25 hydroxy vitamin D [25(OH)D], adipokines levels, and insulin resistance have been reported. The aim of this study was to explore the effects of cholecalciferol supplementation on vitamin D levels, insulin resistance, leptin, and adiponectin levels in vitamin D-deficient peritoneal dialysis (PD) patients. METHODS: In nineteen vitamin D-deficient PD patients, who were treated with cholecalciferol, fasting serum glucose, insulin, adiponectin, leptin, 25(OH)D and parathyroid hormone (PTH) were measured before and after cholecalciferol replacement therapy. Eighteen (94.7 %) PD patients with vitamin D deficiency were receiving active vitamin D compounds (alphacalciferol) for PTH control. Alphacalciferol dosing was kept constant during treatment with cholecalciferol. RESULTS: While mean 25(OH)D significantly increased from (10.2 ± 4.9 ng/ml) to (82.9 ± 56.5 ng/ml) (p < 0.05), mean homeostatic model assessment-insulin resistance index significantly decreased from (4.6 ± 3.6) to (2.8 ± 2.0) after cholecalciferol replacement therapy (p < 0.05). Serum leptin levels (12.9 ± 17.6 ng/ml) significantly increased (18.1 ± 19.5 ng/ml) (p < 0.05), while there was no change in serum adiponectin, calcium, and phosphate after vitamin D replacement. Serum PTH levels significantly decreased from 551.9 ± 276.6 pg/ml to 434.0 ± 273.4 ng/ml. CONCLUSIONS: Cholecalciferol replacement therapy significantly decreases PTH levels and insulin resistance. The results of this study need to be confirmed in larger clinical trials.
OBJECTIVE: Associations between 25 hydroxy vitamin D [25(OH)D], adipokines levels, and insulin resistance have been reported. The aim of this study was to explore the effects of cholecalciferol supplementation on vitamin D levels, insulin resistance, leptin, and adiponectin levels in vitamin D-deficient peritoneal dialysis (PD) patients. METHODS: In nineteen vitamin D-deficient PDpatients, who were treated with cholecalciferol, fasting serum glucose, insulin, adiponectin, leptin, 25(OH)D and parathyroid hormone (PTH) were measured before and after cholecalciferol replacement therapy. Eighteen (94.7 %) PDpatients with vitamin D deficiency were receiving active vitamin D compounds (alphacalciferol) for PTH control. Alphacalciferol dosing was kept constant during treatment with cholecalciferol. RESULTS: While mean 25(OH)D significantly increased from (10.2 ± 4.9 ng/ml) to (82.9 ± 56.5 ng/ml) (p < 0.05), mean homeostatic model assessment-insulin resistance index significantly decreased from (4.6 ± 3.6) to (2.8 ± 2.0) after cholecalciferol replacement therapy (p < 0.05). Serum leptin levels (12.9 ± 17.6 ng/ml) significantly increased (18.1 ± 19.5 ng/ml) (p < 0.05), while there was no change in serum adiponectin, calcium, and phosphate after vitamin D replacement. Serum PTH levels significantly decreased from 551.9 ± 276.6 pg/ml to 434.0 ± 273.4 ng/ml. CONCLUSIONS:Cholecalciferol replacement therapy significantly decreases PTH levels and insulin resistance. The results of this study need to be confirmed in larger clinical trials.
Authors: H Taskapan; F F Ersoy; P S Passadakis; P Tam; D E Memmos; K P Katopodis; C Ozener; F Akcicek; T Camsari; K Ates; R Ataman; J G Vlachojannis; N A Dombros; C Utas; T Akpolat; S Bozfakioglu; G Wu; I Karayaylali; T Arinsoy; C P Stathakis; M Yavuz; D J Tsakiris; A D Dimitriades; M E Yilmaz; M Gültekin; D G Oreopoulos Journal: Clin Nephrol Date: 2006-10 Impact factor: 0.975
Authors: Jared P Reis; Denise von Mühlen; Donna Kritz-Silverstein; Deborah L Wingard; Elizabeth Barrett-Connor Journal: Diabetes Care Date: 2007-03-10 Impact factor: 19.112
Authors: Harini Sarathy; Vedatrayee Pramanik; Jared Kahn; Matthew K Abramowitz; Kristen Meier; Preeti Kishore; Michal L Melamed Journal: Int Urol Nephrol Date: 2015-01-31 Impact factor: 2.370
Authors: Yusuf Bilen; Erdem Cankaya; Nurhan Bilen; Mustafa Keles; Fuat Erdem; Abdullah Uyanik; M Hamidullah Uyanik Journal: Eurasian J Med Date: 2014-08-26